NOVARTIS COMPLETES THE ACQUISITION OF CELLforCURE, EXPANDING ITS GLOBAL PRODUCTION CAPACITY FOR INNOVATIVE CELL AND GENE THERAPIES.

Save

• CELLforCURE becomes a Novartis group company and joining network of cell and gene sites including Morris Plains (USA) and Stein (Switzerland).

• This acquisition strengthens CAR-T cell therapy manufacturing capacity with potential to expand to other cell and gene therapies in Novartis pipeline.

• The acquisition follows the partnership signed between the two companies in July 2018.